Kleiner Device Labs Presents e-Poster at Southern Neurosurgical Society Meeting

Meeting: "Rethinking Posterior MIS Fusion – Enabling Risk Reduction in Posterior Spinal Surgery"

Kleiner Device Labs (KDL) today announced that an e-Poster has been accepted for the Southern Neurosurgical Society’s 2024 annual conference beginning on March 7 in Orlando.  The e-Poster (#156) highlights research results of new innovations in lumbar spinal implant and grafting technologies to reduce risks from poor/insufficient graft volume and placement, surgical site infection (SSI), collateral tissue damage due to multiple instrument passes, and from extended OR time.  

Posterior approach spine fusion has a number of inherent risks to patients’ health and successful outcomes, as well assignificant frustrations for surgeons, and those became the key objectives of our re-engineering a complete interbody system,said Jeff Kleiner, MD, founder and CEO of KDL.  

Dr. Blake Burkert, of NeuroSpine Group, Eugene, Oregon, noted, I share those concerns and want to minimize risks in my own OR.  Utilizing the new system over the past year has proven to be an effective answer for my PLIF and TLIF procedures and has transformed my thinking on the posterior approach to treating spine conditions.

The company will attend the meeting and looks forward to demonstrating the new KG®2 Surge® flow-thru interbody system to surgeons. The first 50 cases with the new KG 2 Surge demonstrated an average of 10ml of bone graft delivered per disc space and an average of 8 minutes total elapsed time for trial, cage placement, grafting and release of the implant.  

The e-Poster presentation will be available at the meting and afterwards on the company’s web site.

For KG2 videos and information, please go to the company’sweb site.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.